Philip Morris International Announces $1.30 Dividend

Philip Morris International Inc. has declared a regular quarterly dividend of $1.30 per common share, payable on April 9, 2024, to shareholders of record as of March 21, 2024. The ex-dividend date is March 20, 2024.

In 2022, Philip Morris International (PMI) acquired Swedish Match, a leader in oral nicotine delivery, creating a global smoke-free champion led by the companies’ IQOS and Zyn brands.

As of December 31, 2023, PMI's smoke-free products were available for sale in 84 markets, and an estimated 20.8 million adults around the world had already switched to IQOS and stopped smoking. Smoke-free products accounted for approximately 37% of PMI’s total full-year 2023 net revenues.

PMI has also announced its ambition to expand into wellness and healthcare areas, aiming to enhance life through the delivery of seamless health experiences through its Vectura Fertin Pharma business.

It's important to note the evolution of PMI's portfolio for the long term, which now includes products outside of the tobacco and nicotine sector. Since 2008, PMI has invested $12.5 billion to develop, scientifically substantiate, and commercialize innovative smoke-free products for adults who would otherwise continue to smoke, with the goal of completely ending the sale of cigarettes.

The company's shares now trading at a price of $91.5. For the full picture, make sure to review Philip Morris International's 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.